tenapanor IBS-C
Selected indexed studies
- Tenapanor for Irritable Bowel Syndrome With Constipation (IBS-C): A Systematic Review of Randomized Trials Assessing Food and Drug Administration (FDA) Composite Response, Durability, and Risk-of-Bias (RoB-2). (Cureus, 2025) [PMID:41158898]
- Patient-Provider Conversation About IBS-C Treatment With Tenapanor. (Gastroenterol Hepatol (N Y), 2025) [PMID:40893826]
- AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Constipation. (Gastroenterology, 2022) [PMID:35738724]
_Worker-drafted node — pending editorial review._
Connections
tenapanor IBS-C is a side effect of
Sources
- AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Constipation. (2022) pubmed
- Tenapanor for Irritable Bowel Syndrome With Constipation (IBS-C): A Systematic Review of Randomized Trials Assessing Food and Drug Administration (FDA) Composite Response, Durability, and Risk-of-Bias (RoB-2). (2025) pubmed
- Patient-Provider Conversation About IBS-C Treatment With Tenapanor. (2025) pubmed
- Tenapanor: First Approval. (2019) pubmed
- Efficacy and Safety of Tenapanor in IBS-C: A Systematic Review and Meta-Analysis. (2025) pubmed
- Comparing the Efficacy of Tenapanor in IBS-C in Hispanic Versus Non-Hispanic Patients: A Post Hoc Analysis of Patients in the Phase 3 T3MPO-1 and T3MPO-2 Studies. (2024) pubmed
- Tenapanor is associated with earlier and sustained symptom relief in IBS-C: a post hoc analysis. (2026) pubmed
- Tenapanor Improves Abdominal Bloating Symptoms in Patients With IBS-C Experiencing Moderate-to-Severe Bloating. (2025) pubmed
- Treatment Satisfaction With Tenapanor: Real-World Survey of Patients With IBS-C. (2025) pubmed
- Efficacy of Tenapanor in Patients With IBS-C: A Post Hoc Analysis of Patients With and Without Prior Use of Other IBS-C Prescription Medications From the Phase 3 T3MPO 1 and T3MPO-2 Studies. (2024) pubmed